A new study published in Nature's cancer journal Oncogene highlights the effectiveness of MDX-124, the first therapeutic drug to target annexin-A1, a protein which is overexpressed in several cancer types and promotes tumour progression.
from News Medical Medical Research News Feed https://ift.tt/n1i5XLB
0 Comments